New cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT05654779
Summary
This early-phase study tested the safety and initial effects of a new type of CAR-T cell therapy called LCAR-AMDR in a small group of patients with acute myeloid leukemia (AML) that had returned or not responded to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them in a lab to better target cancer cells, and then infusing them back into the patient. The main goals were to find a safe dose and see if the treatment could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Gobroad BoRen Hospital
Beijing, Beijing Municipality, 100070, China
-
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.